BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 29289361)

  • 21. Lymphomas arising in immune-privileged sites: insights into biology, diagnosis, and pathogenesis.
    King RL; Goodlad JR; Calaminici M; Dotlic S; Montes-Moreno S; Oschlies I; Ponzoni M; Traverse-Glehen A; Ott G; Ferry JA
    Virchows Arch; 2020 May; 476(5):647-665. PubMed ID: 31863183
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diffuse large B-cell lymphoma.
    Li S; Young KH; Medeiros LJ
    Pathology; 2018 Jan; 50(1):74-87. PubMed ID: 29167021
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Primary testicular diffuse large B-cell lymphoma shows an activated B-cell-like phenotype.
    Li D; Xie P; Mi C
    Pathol Res Pract; 2010 Sep; 206(9):611-5. PubMed ID: 20627604
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of OCT4 and SALL4 in Diffuse Large B-cell Lymphoma: An Analysis of 145 Consecutive Cases and Testicular Lymphomas.
    Williams AS; Shawwa A; Merrimen J; Dakin Haché K
    Am J Surg Pathol; 2016 Jul; 40(7):950-7. PubMed ID: 27035612
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Loss of 5-hydroxymethylcytosine as a Poor Prognostic Factor for Primary Testicular Diffuse Large B-cell Lymphoma.
    Shen Y; Wang L; Ou J; Wang B; Cen X
    Int J Med Sci; 2022; 19(2):225-232. PubMed ID: 35165508
    [No Abstract]   [Full Text] [Related]  

  • 26. Mutational landscape of B-cell post-transplant lymphoproliferative disorders.
    Menter T; Juskevicius D; Alikian M; Steiger J; Dirnhofer S; Tzankov A; Naresh KN
    Br J Haematol; 2017 Jul; 178(1):48-56. PubMed ID: 28419429
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular pathological analysis of testicular diffuse large cell lymphomas.
    Hyland J; Lasota J; Jasinski M; Petersen RO; Nordling S; Miettinen M
    Hum Pathol; 1998 Nov; 29(11):1231-9. PubMed ID: 9824100
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sphingosine-1-phosphate receptor 1 as a prognostic biomarker and therapeutic target for patients with primary testicular diffuse large B-cell lymphoma.
    Koresawa R; Yamazaki K; Oka D; Fujiwara H; Nishimura H; Akiyama T; Hamasaki S; Wada H; Sugihara T; Sadahira Y
    Br J Haematol; 2016 Jul; 174(2):264-74. PubMed ID: 27061580
    [TBL] [Abstract][Full Text] [Related]  

  • 29. RelA NF-κB subunit activation as a therapeutic target in diffuse large B-cell lymphoma.
    Zhang M; Xu-Monette ZY; Li L; Manyam GC; Visco C; Tzankov A; Wang J; Montes-Moreno S; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; Han van Krieken J; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Parsons BM; Winter JN; Piris MA; Medeiros LJ; Pham LV; Young KH
    Aging (Albany NY); 2016 Dec; 8(12):3321-3340. PubMed ID: 27941215
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oncogenic CARMA1 couples NF-κB and β-catenin signaling in diffuse large B-cell lymphomas.
    Bognar MK; Vincendeau M; Erdmann T; Seeholzer T; Grau M; Linnemann JR; Ruland J; Scheel CH; Lenz P; Ott G; Lenz G; Hauck SM; Krappmann D
    Oncogene; 2016 Aug; 35(32):4269-81. PubMed ID: 26776161
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The biological and clinical impact of inhibition of NF-κB-initiated apoptosis in diffuse large B cell lymphoma (DLBCL).
    Bavi P; Uddin S; Bu R; Ahmed M; Abubaker J; Balde V; Qadri Z; Ajarim D; Al-Dayel F; Hussain AR; Al-Kuraya KS
    J Pathol; 2011 Jul; 224(3):355-66. PubMed ID: 21506127
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical and pathological features of testicular diffuse large B-cell lymphoma: a heterogeneous disease.
    Kuper-Hommel MJ; Janssen-Heijnen ML; Vreugdenhil G; Krol AD; Kluin-Nelemans HC; Coebergh JW; van Krieken JH
    Leuk Lymphoma; 2012 Feb; 53(2):242-6. PubMed ID: 21787261
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activating mutations affecting the NF-kappa B pathway and EZH2-mediated epigenetic regulation are rare events in primary mediastinal large B-cell lymphoma.
    Gebauer N; Hardel TT; Gebauer J; Bernard V; Merz H; Feller AC; Rades D; Biersack H; Lehnert H; Thorns C
    Anticancer Res; 2014 Oct; 34(10):5503-7. PubMed ID: 25275047
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P-Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases.
    Dubois S; Viailly PJ; Bohers E; Bertrand P; Ruminy P; Marchand V; Maingonnat C; Mareschal S; Picquenot JM; Penther D; Jais JP; Tesson B; Peyrouze P; Figeac M; Desmots F; Fest T; Haioun C; Lamy T; Copie-Bergman C; Fabiani B; Delarue R; Peyrade F; André M; Ketterer N; Leroy K; Salles G; Molina TJ; Tilly H; Jardin F
    Clin Cancer Res; 2017 May; 23(9):2232-2244. PubMed ID: 27923841
    [No Abstract]   [Full Text] [Related]  

  • 35. [Molecular pathogenesis and treatment strategy in diffuse large B-cell lymphoma].
    Shimada K
    Rinsho Ketsueki; 2017; 58(10):2033-2042. PubMed ID: 28978846
    [TBL] [Abstract][Full Text] [Related]  

  • 36. "Quadruple-hit" primary testicular diffuse large B-cell lymphoma with MYD88 L265P mutation, IGH::MYC, and IRF4- and BCL6-rearrangements.
    Bruehl FK; Ketterling RP; Rimsza LM; Santos EF; McPhail ED
    J Hematop; 2023 Sep; 16(3):161-165. PubMed ID: 38175404
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling.
    Lam LT; Davis RE; Pierce J; Hepperle M; Xu Y; Hottelet M; Nong Y; Wen D; Adams J; Dang L; Staudt LM
    Clin Cancer Res; 2005 Jan; 11(1):28-40. PubMed ID: 15671525
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Primary central nervous system diffuse large B-cell lymphoma shows an activated B-cell-like phenotype with co-expression of C-MYC, BCL-2, and BCL-6.
    Li X; Huang Y; Bi C; Yuan J; He H; Zhang H; Yu Q; Fu K; Li D
    Pathol Res Pract; 2017 Jun; 213(6):659-665. PubMed ID: 28552541
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High prevalence of the MYD88 mutation in testicular lymphoma: Immunohistochemical and genetic analyses.
    Oishi N; Kondo T; Nakazawa T; Mochizuki K; Tanioka F; Oyama T; Yamamoto T; Iizuka J; Tanabe K; Shibata N; Kirito K; Katoh R
    Pathol Int; 2015 Oct; 65(10):528-35. PubMed ID: 26388135
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of TNF-receptor associated factor 2 correlates with poor progression-free survival time in ABC-like primary nodal diffuse large B-cell lymphomas.
    van Galen JC; Muris JJ; Giroth CP; Vos W; Ossenkoppele GJ; Meijer CJ; Oudejans JJ
    Histopathology; 2008 Apr; 52(5):578-84. PubMed ID: 18312353
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.